{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:19:19Z","timestamp":1794586759764,"version":"4.9.1"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"1147","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":850,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The severe acute respiratory syndrome (SARS) coronavirus-2 is a novel coronavirus belonging to the family Coronaviridae and is now known to be responsible for the outbreak of a series of recent acute atypical respiratory infections originating in Wuhan, China. The disease caused by this virus, termed coronavirus disease 19 or simply COVID-19, has rapidly spread throughout the world at an alarming pace and has been declared a pandemic by the WHO on March 11, 2020. In this review, an update on the pathophysiology, clinical presentation and the most recent management strategies for COVID-19 has been described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A search was conducted for literature and various articles\/case reports from 1997 to 2020 in PUBMED\/MEDLINE for the keywords coronavirus, SARS, Middle East respiratory syndrome and mRNA virus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and Conclusions<\/jats:title><jats:p>COVID-19 has now spread globally with increasing morbidity and mortality among all populations. In the absence of a proper and effective antibody test, the diagnosis is presently based on a reverse-transcription PCR of nasopharyngeal and oropharyngeal swab samples. The clinical spectrum of the disease presents in the form of a mild, moderate or severe illness. Most patients are either asymptomatic carriers who despite being without symptoms have the potential to be infectious to others coming in close contact, or have a mild influenza-like illness which cannot be differentiated from a simple upper respiratory tract infection. Moderate and severe cases require hospitalisation as well as intensive therapy which includes non-invasive as well as invasive ventilation, along with antipyretics, antivirals, antibiotics and steroids. Complicated cases may require treatment by immunomodulatory drugs and plasma exchange therapy. The search for an effective vaccine for COVID-19 is presently in full swing, with pharmaceutical corporations having started human trials in many countries.<\/jats:p><\/jats:sec>","DOI":"10.1136\/postgradmedj-2020-138577","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T21:20:48Z","timestamp":1602105648000},"page":"312-320","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":570,"title":["COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment"],"prefix":"10.1093","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-3231","authenticated-orcid":false,"given":"Anant","family":"Parasher","sequence":"first","affiliation":[{"name":"Medicine, Guru Teg Bahadur Hospital , New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"108427","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: a review [published online ahead of print, 2020 Apr 20]","volume":"215","author":"Yuki","year":"2020","journal-title":"Clin Immunol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"Group A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N Engl J Med"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume-title":"Cell Mol Immunol","author":"Zheng","year":"2020"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(20)30230-9","article-title":"Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study","volume":"20","author":"Zhang","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023041707101265300_","volume-title":"Features, evaluation and treatment coronavirus (COVID-19). Stat pearls [internet]","author":"Cascella","year":"2020"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3389\/fmicb.2020.01302","article-title":"Main clinical features of COVID-19 and potential prognostic and therapeutic value of the microbiota in SARS-CoV-2 Infections","volume":"11","author":"He","year":"2020","journal-title":"Front Microbiol"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","article-title":"The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex","volume":"77","author":"Bosch","year":"2003","journal-title":"J Virol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","article-title":"Structure analysis of the receptor binding of 2019-nCoV [published online ahead of print, 2020 Feb 17]","volume":"525","author":"Chen","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B beta coronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.gt.3302479","article-title":"siRNA targeting the leader sequence of SARS-CoV inhibits virus replication","volume":"12","author":"Li","year":"2005","journal-title":"Gene Ther"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1073\/pnas.0809524106","article-title":"Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites","volume":"106","author":"Belouzard","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/v4061011","article-title":"Mechanisms of coronavirus cell entry mediated by the viral spike protein","volume":"4","author":"Belouzard","year":"2012","journal-title":"Viruses"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3527(08)60286-9","article-title":"The molecular biology of coronaviruses","volume":"48","author":"Lai","year":"1997","journal-title":"Adv Virus Res"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.7150\/ijbs.45498","article-title":"Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"2000607","DOI":"10.1183\/13993003.00607-2020","article-title":"Pathogenesis of COVID-19 from a cell biology perspective","volume":"55","author":"Mason","year":"2020","journal-title":"Eur Respir J"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese centre for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"15511","DOI":"10.1128\/JVI.79.24.15511-15524.2005","article-title":"Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs","volume":"79","author":"Sims","year":"2005","journal-title":"J Virol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1373\/clinchem.2005.054460","article-title":"Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome","volume":"51","author":"Tang","year":"2005","journal-title":"Clin Chem"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","article-title":"Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China","volume-title":"Emerg Infect Dis","author":"Liu","year":"2020"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm6909e1","article-title":"Active monitoring of persons exposed to patients with confirmed COVID-19: United States, January\u2013February 2020","volume-title":"MMWR Morb Mortal Wkly Rep","author":"Burke","year":"2020"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2020.3227","article-title":"Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient","volume":"323","author":"Ong","year":"2020","journal-title":"JAMA"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(03)13410-1","article-title":"Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in hong kong","volume":"361","author":"Donnelly","year":"2003","journal-title":"Lancet"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of COVID-19 in New York city","volume":"382","author":"Goyal","year":"2020","journal-title":"N Engl J Med"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","volume":"323","author":"Young","year":"2020","journal-title":"JAMA"},{"key":"2023041707101265300_","article-title":"Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the hong kong cohort and systematic review and meta-analysis","volume-title":"Gastroenterology","author":"Cheung","year":"2020"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"e0123126","DOI":"10.1371\/journal.pone.0123126","article-title":"Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV)","volume":"10","author":"Bhadra","year":"2015","journal-title":"PLoS One"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1128\/JCM.01224-15","article-title":"Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic Coronaviruses","volume":"53","author":"Chan","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/22221751.2020.1729071","article-title":"Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2023041707101265300_","article-title":"Sensitivity of chest CT for COVID-19: comparison to RT-PCR","volume-title":"Radiology","author":"Fang","year":"2020"},{"key":"2023041707101265300_","article-title":"Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion","volume-title":"Radiology","author":"Huang","year":"2020"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"106504","DOI":"10.1016\/j.intimp.2020.106504","article-title":"The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients","volume":"84","author":"Yang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.bja.2020.02.020","article-title":"High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial [published online ahead of print, 2020 Mar 19]","volume":"125","author":"Wu","year":"2020","journal-title":"Br J Anaesth"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjh.16727","article-title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action","volume":"189","author":"Kollias","year":"2020","journal-title":"Br J Haematol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13054-020-02925-3","article-title":"COVID-19 and ECMO: the interplay between coagulation and inflammation: a narrative review","volume":"24","author":"Kowalewski","year":"2020","journal-title":"Crit Care"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1001\/jama.2015.13896","article-title":"Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial","volume":"314","author":"Bacharier","year":"2015","journal-title":"JAMA"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients","volume":"31","author":"Lee","year":"2004","journal-title":"J Clin Virol"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"2023041707101265300_","first-page":"NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 - preliminary report [published online ahead of print, 2020 may 22]","volume-title":"N Engl J Med","author":"Beigel","year":"2020"},{"key":"2023041707101265300_","article-title":"Remdesivir for 5 or 10 days in patients with severe COVID-19 [published online ahead of print, 2020 May 27]","volume-title":"N Engl J Med","author":"Goldman","year":"2020"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"e00399","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023041707101265300_","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong Med J"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option","volume":"92","author":"Yao","year":"2020","journal-title":"J Med Virol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"2023041707101265300_","article-title":"PubChem Database","volume-title":"Favipiravir, CID=492405","author":"National Center for Biotechnology Information"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12967-020-02333-9","article-title":"Anti-IL6R role in treatment of COVID-19-related ARDS","volume":"18","author":"Buonaguro","year":"2020","journal-title":"J Transl Med"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","author":"Guaraldi","year":"2020"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Biot","year":"2006","journal-title":"J Med Chem"},{"key":"2023041707101265300_","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) [published online ahead of print, 2020 mar 9]","volume-title":"Clin Infect Dis","author":"Yao","year":"2020"},{"key":"2023041707101265300_","first-page":"105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume-title":"Int J Antimicrob Agents","author":"Gautret","year":"2020"},{"key":"2023041707101265300_","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19) [published online ahead of print, 2020 May 1]","volume-title":"JAMA Cardiol","author":"Mercuro","year":"2020"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","volume":"55","author":"Zhai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV: a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2023041707101265300_"},{"key":"2023041707101265300_"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/97\/1147\/312\/49933014\/postgradmedj-97-312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/97\/1147\/312\/49933014\/postgradmedj-97-312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T07:07:13Z","timestamp":1696835233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/97\/1147\/312\/6969661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":91,"journal-issue":{"issue":"1147","published-online":{"date-parts":[[2020,9,25]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2020-138577","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"value":"1469-0756","type":"electronic"},{"value":"0032-5473","type":"print"}],"subject":[],"published-other":{"date-parts":[[2021,5]]},"published":{"date-parts":[[2020,9,25]]}}}